Book of Abstracts - Ruhr-Universität Bochum
Book of Abstracts - Ruhr-Universität Bochum Book of Abstracts - Ruhr-Universität Bochum
P-31 ISBOMC `10 5.7 – 9.7. 2010 Ruhr-Universität Bochum Synthesis, Structures, Characterization and Biological Activities of Some Diorganotin(IV) Complexes See Mun Lee, *a H. Mohd. Ali, a and K. M. Lo a a University of Malaya, Faculty of Science, Department of Chemistry, 50603 Kuala Lumpur,Malaysia. E-mail: smlee@um.edu.my Metal complexes are widely prepared and have been successfully used in the treatment of numerous human diseases including cancer. Organotin(IV) complexes have been widely studied for their biological activities such as anticancer, antihistamine, antifungal and many others. Schiff base derived from substituted salicylaldehyde has been widely used as polydentate ligands in the preparation of metal complexes. In our present studies, a series of Schiff base ligands were prepared by reacting 3hydroxy-2-naphthoic hydrazide with substituted 2-hydroxyacetophenone. The diorganotin complexes were subsequently prepared by adding the ligands with diorganotin dichloride or oxide in 1:1 molar ratio and were characterized by various spectroscopic methods including IR, NMR spectroscopies. The X-ray structures of some of the diorganotin complexes namely {[1-(5-Bromo-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphthohydrazidato}dimethyltin(IV) {[1-(5-Bromo-2 oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dibutyltin(IV) {[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV) and {[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV) have been determined using single crystal X-ray diffractometry. The in vitro cytotoxic activity of the Schiff base ligands and diorganotin complexes has been evaluated against several cancer cell-lines such as HT-29, SKOV-3 and MCF7. References 1. M. Gielen, Coord. Chem. Rev. 1996, 151, 41-51. 2. A. J. Crowe, P. J. Smith, C. J. Cardin, H. E. Parge, F. E. Smith. Cancer Lett. 1984, 24 45-48. 89
P-32 ISBOMC `10 5.7 – 9.7. 2010 Ruhr-Universität Bochum Organometallic Iridium Anticancer Complexes Zhe Liu, Abraha Habtemariam, Ana Pizarri, Sally Fletcher, Guy Clarkson and Peter J. Sadler Department of Chemistry, University of Warwick, Coventry CV4 7AL, U.K. E-mail: Z.Liu.2@warwick.ac.uk Cisplatin has been used to treat various types of cancers for over 30 years, however, a number of serious side-effects of cisplatin have stimulated the long quest for other metal-based anticancer agents, especially drugs which possess a wider range of anticancer activity and with fewer side effects than cisplatin. There is much current interest in the design of ruthenium 1 and osmium 2 complexes as anticancer agents, but only a small amount of work has been done to investigate the antitumour activity of iridium complexes. 3 Here we report the synthesis and characterization of a wide range of Ir(III) cyclopentadienyl complexes. We have studied their solid state structures, hydrolysis rates, reactivity towards nucleobases and acidity of aqua complexes. Their cell uptake and distribution and toxicity towards cancer cells have been studied and correlated with their chemical properties. Both the chemical and biological activity of these complexes show a strong dependence on the nature of the substituents on the cyclopentadienyl and the other ligands in the complexes. Acknowledgements: We thank WPRS (scholarship for Z.L), ERC (award for P.J.S.), EDRF and AWM for Science City funding, and members of COST Action D39 for stimulating discussions. References 1. (a) A. Habtemariam, M. Melchart, R. Fernndez, S. Parsons, I. D. H. Oswald, A. Parkin, F. P. A. Fabbiani, J. E. Davidson, A. Dawson, R. E. Aird, D. I. Jodrell, P. J. Sadler, J. Med. Chem., 2006, 49, 6858-6868. (b) J. M. Redemaker-Lakhai, D. van den. Bongard, D. Pluim, J. H. Beijnen, J. H. M. Schellens, Clin. Cancer Res. 2004, 10, 3717–3727. (c) I. Bratsos, S. Jedner, T. Gianferrara, E. Alessio, Chimia 2007, 61, 692-697. 2. (a) A. F. A. Peacock, S. Parsons, P. J. Sadler, J. Am. Chem. Soc. 2007, 129, 3348-3357. (b) P.C. A. Bruijnincx and P. J. Sadler, Adv. Inorg. Chem. 2009, 61, 1-62. 3. S. Schäfer, I. Ott, R. Gust, W. S. Sheldrick, Eur. J. Inorg. Chem. 2007, 3034-3046. 90
- Page 39 and 40: OP-22 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 41 and 42: OP-24 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 43 and 44: OP-26 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 45 and 46: OP-28 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 47 and 48: OP-30 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 49 and 50: OP-32 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 51 and 52: OP-34 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 53 and 54: OP-36 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 55 and 56: OP-38 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 57 and 58: OP-40 ISBOMC `10 5.7 - 9.7. 2010 Ru
- Page 59 and 60: ISBOMC `10 5.7 - 9.7. 2010 Ruhr-Uni
- Page 61 and 62: P-02 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 63 and 64: P-04 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 65 and 66: P-06 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 67 and 68: P-08 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 69 and 70: P-10 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 71 and 72: P-12 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 73 and 74: P-14 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 75 and 76: P-16 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 77 and 78: P-18 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 79 and 80: P-20 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 81 and 82: P-22 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 83 and 84: P-24 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 85 and 86: P-26 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 87 and 88: P-28 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 89: P-30 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 93 and 94: P-34 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 95 and 96: P-36 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 97 and 98: P-38 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 99 and 100: P-40 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 101 and 102: P-42 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 103 and 104: P-44 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 105 and 106: P-46 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 107 and 108: P-48 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 109 and 110: P-50 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 111 and 112: P-52 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 113 and 114: P-54 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 115 and 116: P-56 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 117 and 118: P-58 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 119 and 120: P-60 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 121 and 122: P-62 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 123 and 124: P-64 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 125 and 126: P-66 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 127 and 128: P-68 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 129 and 130: P-70 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 131 and 132: P-72 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 133 and 134: P-74 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 135 and 136: P-76 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 137 and 138: P-78 ISBOMC `10 5.7 - 9.7. 2010 Ruh
- Page 139 and 140: P-80 ISBOMC `10 5.7 - 9.7. 2010 Ruh
P-31<br />
ISBOMC `10 5.7 – 9.7. 2010 <strong>Ruhr</strong>-<strong>Universität</strong> <strong>Bochum</strong><br />
Synthesis, Structures, Characterization and Biological Activities <strong>of</strong> Some<br />
Diorganotin(IV) Complexes<br />
See Mun Lee, *a H. Mohd. Ali, a and K. M. Lo a<br />
a University <strong>of</strong> Malaya, Faculty <strong>of</strong> Science, Department <strong>of</strong> Chemistry, 50603 Kuala Lumpur,Malaysia.<br />
E-mail: smlee@um.edu.my<br />
Metal complexes are widely prepared and have been successfully used in the treatment <strong>of</strong> numerous<br />
human diseases including cancer. Organotin(IV) complexes have been widely studied for their<br />
biological activities such as anticancer, antihistamine, antifungal and many others. Schiff base derived<br />
from substituted salicylaldehyde has been widely used as polydentate ligands in the preparation <strong>of</strong><br />
metal complexes. In our present studies, a series <strong>of</strong> Schiff base ligands were prepared by reacting 3hydroxy-2-naphthoic<br />
hydrazide with substituted 2-hydroxyacetophenone. The diorganotin complexes<br />
were subsequently prepared by adding the ligands with diorganotin dichloride or oxide in 1:1 molar<br />
ratio and were characterized by various spectroscopic methods including IR, NMR spectroscopies.<br />
The X-ray structures <strong>of</strong> some <strong>of</strong> the diorganotin complexes namely<br />
{[1-(5-Bromo-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphthohydrazidato}dimethyltin(IV)<br />
{[1-(5-Bromo-2 oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dibutyltin(IV)<br />
{[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV) and<br />
{[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV)<br />
have been determined using single crystal X-ray diffractometry. The in vitro cytotoxic activity <strong>of</strong> the<br />
Schiff base ligands and diorganotin complexes has been evaluated against several cancer cell-lines<br />
such as HT-29, SKOV-3 and MCF7.<br />
References<br />
1. M. Gielen, Coord. Chem. Rev. 1996, 151, 41-51.<br />
2. A. J. Crowe, P. J. Smith, C. J. Cardin, H. E. Parge, F. E. Smith. Cancer Lett. 1984, 24 45-48.<br />
89